A PHASE III, MULTICENTRE, RANDOMISED, DOUBLE BLIND, PARALLEL GROUP, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONE OR MORE INTRADETRUSOR TREATMENTS OF 600 OR 800 UNITS OF DYSPORT® FOR THE TREATMENT OF URINARY INCONTINENCE IN SUBJECTS WITH NEUROGENIC DETRUSOR OVERACTIVITY DUE TO SPINAL CORD INJURY OR MULTIPLE SCLEROSIS Save

Date Added
August 9th, 2016
PRO Number
Pro00058027
Researcher
Lindsey Cox

Silhouette
Keywords
Bladder, Multiple Sclerosis, Spinal Cord
Summary

The main objective of this study is to evaluate if Dysport® is effective and safe for the treatment of urinary incontinence due to NDO.

Dysport® contains a toxin that is produced from bacteria. The toxin is called Botulinum toxin A and it is known that this toxin causes muscles that are contracting too much to relax once the muscles are injected with the toxin. This relaxation usually lasts for several months before treatment needs to be given again.

Institution
MUSC
Recruitment Contact
Jessica Jenkins
843-876-0630
843792-2325

Change_preferences

-- OR --

Create_login